Last reviewed 2026-06-03 · How we verify

CXL-1427

Bristol-Myers Squibb · Phase 2 active Small molecule ✓ Verified Jun 2026 Quality 0/100

CXL-1427 is a Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 2 development. Also known as: BMS-986231.

CXL-1427 is a small molecule experimental drug, discovered by Cardioxyl Pharmaceuticals and later acquired by Bristol-Myers Squibb. It is being studied in a Phase IIa clinical trial for the treatment of Heart Failure, Decompensated Heart Failure, and Acute Heart Failure.

Likelihood of approval

18.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Bristol-Myers Squibb is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CXL-1427
Also known as	BMS-986231
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CXL-1427 CI brief — competitive landscape report
CXL-1427 updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI

Frequently asked questions about CXL-1427

What is CXL-1427?

CXL-1427 is a Small molecule drug developed by Bristol-Myers Squibb.

Who makes CXL-1427?

CXL-1427 is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).

Is CXL-1427 also known as anything else?

CXL-1427 is also known as BMS-986231.

What development phase is CXL-1427 in?

CXL-1427 is in Phase 2.

Manufacturer: Bristol-Myers Squibb — full pipeline
Also known as: BMS-986231

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing